MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
详细信息 查看全文
- 作者：Juliana M. Benito1 ; Laura Godfrey2 ; Kensuke Kojima3 ; Leah Hogdal4 ; Mark Wunderlich5 ; Huimin Geng6 ; Isabel Marzo7 ; Karine G. Harutyunyan1 ; Leonard Golfman8 ; Phillip North2 ; Jon Kerry2 ; Erica Ballabio2 ; Triona Ní ; Chonghaile9 ; Oscar Gonzalo7 ; Yihua Qiu1 ; Irmela Jeremias10 ; LaKiesha Debose1 ; Eric O&rsquo ; Brien5 ; Helen Ma1 ; Ping Zhou1 ; Rodrigo Jacamo1 ; Eugene Park6 ; Kevin R. Coombes11 ; Nianxiang Zhang11 ; Deborah A. Thomas1 ; Susan O&rsquo ; Brien1 ; Hagop M. Kantarjian1 ; Joel D. Leverson12 ; Steven M. Kornblau1 ; Michael Andreeff1 ; Markus Mü ; schen6 ; Patrick A. Zweidler-McKay8 ; James C. Mulloy5 ; Anthony Letai4 ; Thomas A. Milne2 ; thomas.milne@imm.ox.ac.uk" class="auth_mail" title="E-mail the corresponding author ; Marina Konopleva1 ; mkonople@mdanderson.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：apoptosis pathways ; leukemias ; bcl-2 family members ; MLL/AF4 ; DOT1L ; H3K79 methylation
- 刊名：Cell Reports
- 出版年：2015
- 出版时间：29 December 2015
- 年：2015
- 卷：13
- 期：12
- 页码：2715-2727
- 全文大小：3280 K
文摘
MLLr ALL blasts express high levels of BCL-2, BAX, and BIM
MLL/AF4 activates BCL2 through H3K79 methylation
MLLr ALL cells are exquisitely sensitive to BCL-2 antagonist ABT-199
ABT-199 treatment synergizes with H3K79 methylation inhibitors on MLLr samples